tcm55
4 months ago
Neuroplasticity, dendritic spines, 1hr 40mins. He sites many papers, mostly in mouse/rat trials, in this presentation where neuroplasticity is observed, but it seems that the AGN 'microdosing for Stroke' concept is unique.
Yes, the when and where type of data for the clinical trials could be announced soon. Maybe Oregon where it's legal for research?
I've held this long already and will hold through the finish...
...GLTA...
tcm55
4 months ago
Sure great to see this all finally progressing.
βInvestigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,β said Christopher J. Moreau CEO of Algernon. βAlgernon is a global leader in this important area of research, and we look forward to further advancing the stroke program through our planned Phase 2a DMT Stroke study.β
Phase 2a Stroke Study Design
Subjects with a confirmed diagnosis of ischemic stroke will be randomized in blinded fashion to receive either DMT or placebo. The primary outcome measure of the study will be safety, and information will be gained on measures of efficacy including preservation of brain tissue, motor recovery, depression and numerous biomarkers linked to the pathophysiology of stroke.
The veteran community has discussed TBI and PTSD issues and treatments involving Psycs. This group may also be a area of recruitment for future stroke/TBI research. There are already a few PTSD studies...
...GLTA...
McMagyar
4 months ago
Algernon going to move forward with 40 patient phase 2 for isechemic stroke.
Is there a Stroke Victim advocacy group which could help cover costs?
Canβt wait for results! 6 days of treatment..
40 patients.. normally a clinical trial takes forever..
How common is an ischemic stroke?
Strokes are very common. Worldwide, strokes rank second among the top causes of death. In the United States, they rank fifth. Strokes are also one of the leading causes of disability worldwide. Ischemic strokes make up about 85% of all strokes.
No shortage of need..
Stroke statistics
In 2021, 1 in 6 deaths from cardiovascular disease was due to stroke.1
Every 40 seconds, someone in the United States has a stroke.2 Every 3 minutes and 14 seconds, someone dies of stroke.1
Every year, more than 795,000 people in the United States have a stroke. About 610,000 of these are first or new strokes.2
About 185,000 strokesβnearly 1 in 4βare in people who have had a previous stroke.2
About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked.2
Stroke-related costs in the United States came to nearly $56.5 billion between 2018 and 2019.2 This total includes the cost of health care services, medicines to treat stroke, and missed days of work.
Stroke is a leading cause of serious long-term disability.2 Stroke reduces mobility in more than half of stroke survivors age 65 and older.2
I think the goal will be to administer the first sub psych dose of DMT immediately after diagnosis..
A positive phase 2a.. would be a very large step for algernon
βInvestigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,
shell3
5 months ago
Outstanding: 21,640,762 posted February 8, 2024
Monthly 5th Report for January filed today
https://webfiles.thecse.com/1._Algernon_-_CSE_Form_7_-_January_2024.pdf?vo61Q.9_pMwV5o_dI3dUQifkB4N2s71C
January 30th, 2024 this happened
Additionally, the Company granted 1,625,000 restricted share units (βRSUβ) pursuant to its RSU Plan to executives and directors of the Company and 100,000 stock options, exercisable at $0.075 for two years from the date of grant, to a consultant of the Company. The RSUs and stock options vested on the grant date.